TinyGemsBreaks Archive - Page 117 of 121

ThursdayJun 16, 2022 2:58 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health Conference. The event is slated to take place at the Lotte New York Palace Hotel on June 27, 2022. Drysdale’s fireside chat will be webcast live at 10:30 a.m. ET on the day of the conference. In addition, Drysdale will participate in a panel discussion titled “Navigating Depression: Current Understanding and Future Treatments” at 12:45 p.m. ET. Interested parties should visit…

ThursdayJun 16, 2022 2:30 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces $5M Share Repurchase Program

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors has authorized the repurchase of up to $5 million of its outstanding common shares as market conditions and the company’s liquidity warrant. “We believe that the potential to repurchase our shares at these levels represents a compelling opportunity to deploy available cash to drive shareholder value,” said Luis Merchan, Flora’s chairman and CEO. “Flora continues to move assertively to execute its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses. We are confident…

WednesdayJun 15, 2022 3:09 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance,” a recent article reads. “The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset…

WednesdayJun 15, 2022 12:08 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) to Join Russell 3000(R) Index, Expand Story Among Investment Community

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that it will be added as a member of the Russell 3000(R) index at the conclusion of the 2022 Russell indexes annual reconstitution. This is effective after the U.S. market opens on June 27, 2022, according to a preliminary list of additions posted on June 3, 2022. “Cepton is excited to be joining the Russell 3000(R) index as it enables us to expand awareness of our story among the investment community as we continue to execute against our milestones generating long-term stakeholder value,” said…

TuesdayJun 14, 2022 4:40 pm

TinyGemsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Added to PMLS Menu of Testing Services

Premier Medical Laboratory Services (“PMLS”), a nation-leading advanced medical diagnostics lab, today announced that it has added Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) to its menu of testing services. AditxtScore provides more clarity regarding a patient’s individual immunity profile and allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” said Kevin Murdock, CEO of Premier Medical Laboratory Services. “With AditxtScore, individuals can make more informed decisions about…

TuesdayJun 14, 2022 3:36 pm

TinyGemsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Reaches Agreement with Philip Morris International Inc. (NYSE: PM) for International Electronic Nicotine Delivery System Product Distribution

Kaival Brands (NASDAQ: KAVL), the U.S. distributor of all products manufactured by Bidi Vapor LLC, which are intended for legal-age nicotine users, has inked an international licensing agreement with Philip Morris Products S.A. (“PMPSA”) for the development and distribution of electronic nicotine delivery system ("ENDS") products. Philip Morris Products is a wholly owned affiliate of Philip Morris International Inc. (NYSE: PM), and the agreement, which was finalized on June 13, 2022, covers products for markets outside of the United States. According to the announcement, the agreement between Kaival and PMPSA grants the latter the rights to manufacture, promote, sell and…

FridayJun 10, 2022 4:02 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Robot Roadshow to Take the Spotlight at Kennedy Space Center

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that its Robot Roadshow will land in Florida at the Kennedy Space Center from 10 a.m. to 2 p.m. ET on June 17, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion. The announcement reads, “The Robot Roadshow has completed 45 landings in 16 states and Washington, D.C. to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience…

FridayJun 10, 2022 12:54 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Poised as Industry’s Most Extensive Gaming Portfolio Provider

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has sought to bridge the gap between gaming operators and studios through its GM-X and the launch of its B2B aggregate gaming system, GMX-Ag. “Golden Matrix’s GM-X system has long been established as the industry standard, granting gaming platforms with access to upwards of 10,000 games from a broad array of over 25 gaming studios via a singly gaming API – firmly cementing its position as the industry’s most extensive gaming portfolio provider. The company’s partners dominate the global online gaming market, with GMGI…

FridayJun 10, 2022 12:40 pm

TinyGemsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) Completion of Key Milestones Position It for Success

Flora Growth Corp. (NASDAQ: FLGC) recently announced financial and operating results for the 2021 fiscal year that show the success of its efforts as revenues and profits begin what is expected to be a rapid climb. “The year-end financial results show about $9 million in revenues, which is ‘significantly higher’ than those reported the prior year before the law change and Flora’s IPO launch on the Nasdaq Capital Market. The report maintains the company’s outlook for ending 2022 with revenues of $35 million to $45 million, which would be growth of between 288% and 400% over 2021. Much of Flora’s…

FridayJun 10, 2022 10:48 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”). Cybin applied for IRB approval just last month. According to the announcement, Cybin wholly owned subsidiary Cybin IRL Limited has partnered with Clinilabs Drug Development Corporation to conduct the randomized, double-blind, placebo-controlled study. The study involves participants receiving two administrations of…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks